| Project/Area Number |
10670060
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Environmental physiology (including Physical medicine and Nutritional physiology)
|
|---|
| Research Institution | Yamanashi Medical University |
|---|
Principal Investigator |
ARITA Jun Faculty of Medicine, Yamanashi Medical University, Professor, 医学部, 教授 (80128587)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAKAWA Koji Faculty of Medicine, Yamanashi Medical University, Research associate, 医学部, 助手 (90293472)
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Project Status |
Completed (Fiscal Year 1999)
|
| Budget Amount *help |
¥3,300,000 (Direct Cost: ¥3,300,000)
Fiscal Year 1999: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1998: ¥2,200,000 (Direct Cost: ¥2,200,000)
|
|---|
| Keywords | anterior pituitary gland / cell proliferation / cyclic AMP / MAP kinase / CREB / 増殖 / サククリックAMP |
|---|
| Research Abstract |
We investigated the interaction of two signal transduction pathways of cyclic AMP/protein kinase A (PKA) and MAP kinase cascade which regulate the proliferation of lactotrophs.
(1) The MAP kinase inhibitor PD98059 was effective in inhibiting the mitogenic action not only of insulin but also of forskolin that increased intracellular cyclic AMP levels, suggesting the requirement of the MAP kinase cascade for the mitogenic action of cyclic AMP/PKA.
(2) The PKA inhibitors H89 and KT5720 were effective in inhibiting the mitogenic action not only of forskolin but also of insulin, suggesting the requirement of cyclic AMP/PKA for the mitogenic action of growth factors such as insulin.
(3) Phosphorylated MAP kinase in lactotrophs was immunostained with a selective antibody to estimate the activity of MAP kinase. Although the number of phosphorylated MAP kinase-immunoreactive lactotrophs was altered by dibutyryl cyclic AMP or forskolin, the number of phosphorylated CREB-immunoreactive lactotrophs was increased by forskolin and insulin-like growth factor-1.
(4) The p70S6k inhibitor rapamycin inhibited insulin- or forskolin-induced lactotroph proliferation as well as proliferation induced by estradiol, a physiologically important mitogen. Rapamycin inhibited insulin-, but not forskolin-induced proliferation in the presence of the dopamine agonist bromocriptine, which was a potent antimitogen of lactotrophs. The results suggest MAP kinase- and cyclic AMP/PKA-mediated signals converge at the level of p70S6k or its upstream.
|
